Navigation Links
Lexicon Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
Date:12/10/2007

THE WOODLANDS, Texas, Dec. 10 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that a member of Lexicon senior management will participate in the RBC Capital Markets Healthcare Conference panel Going With Your Gut: New Treatments for GI Disorders at The Westin Times Square Hotel in New York, New York on Wednesday, December 12, 2007 at 8:00 a.m. Eastern Time.

A live audio webcast of the panel presentation may be accessed on Lexicon's corporate website at http://www.lexpharma.com. An archived version of the webcast will be available on the website through December 20, 2007.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome, cognitive disorders, and rheumatoid arthritis. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
2. Lexicon Pharmaceuticals to Present at the UBS Global Life Sciences Conference
3. Lexicon Appoints Judith Swain, M.D. to Board of Directors
4. Lexicon Pharmaceuticals to Present at ThinkEquity ThinkClinic
5. Lexicon Pharmaceuticals to Present at Bio InvestorForum
6. Lexicon to Report Third Quarter 2007 Financial Results on October 30, 2007
7. Lexicon Pharmaceuticals Reports 2007 Third Quarter Financial Results
8. Lexicon Pharmaceuticals to Present at the Piper Jaffray 19th Annual Health Care Conference
9. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
10. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
11. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... , ... The American Academy of Thermology (AAT) has announced that ... Member Certification Qualification Course for Technicians via a two part webinar on July 30 ... detailed review of hardware, software, and camera setup/operations, aligns with the in-person member qualification ...
(Date:2/9/2016)... Lawrenceville, NJ (PRWEB) , ... February 09, 2016 ... ... Diane Dorman, former Vice President for Public Policy for the National Organization for ... and patient advocacy groups to ensure their voices are heard throughout the drug ...
(Date:2/9/2016)... This market research report on the global ... of the market in terms of revenue (USD Million). ... the manufacture of microbiology culture media and related products. ... snapshot providing the overall information of various market segments ... also provides the overall information and data analysis of ...
(Date:2/9/2016)... 2016 Three-Year Initiative Supports Next Generation ... Part in Life-Changing Camp Experiences ... positively affect the lives of children born with rare diseases, as ... SHPG ) is announcing a new initiative designed to positively affect ... the future of rare disease care. --> To mark ...
Breaking Biology Technology:
(Date:1/27/2016)... Jan. 27, 2016  Rite Track, Inc. a leading ... West Chester, Ohio announced today the ... staff, based in Austin, Texas , ... to provide modifications, installations and technical support offerings for ... of PLUS, commented, "PLUS has provided world class service ...
(Date:1/21/2016)... , January 21, 2016 ... to a new market research report "Emotion Detection and ... Others), Software Tools (Facial Expression, Voice Recognition and ... - Global forecast to 2020", published by MarketsandMarkets, ... expected to reach USD 22.65 Billion by 2020, ...
(Date:1/15/2016)... Puerto Rico , Jan. 15, 2016 ... big and small to find new ways to ensure ... culture. iOS and Android ... based on biometrics, transforming it into a hardware authorization ... that users swipe their fingerprint on their KodeKey enabled ...
Breaking Biology News(10 mins):